Cecilia Riani

Dr. Cecilia Riani

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
APAndrea Previtali
Andrea Previtali
IGIsabella Guardamagna
Isabella Guardamagna
SCSilvia Calandra
Silvia Calandra
MSMaryam Shakarami
Maryam Shakarami
LLLEONARDO LONATI
LEONARDO LONATI
Claudia ScottiClaudia Scotti
Claudia Scotti
Triple-negative breast cancer (TNBC) remains one of the most aggressive and therapeutically challenging breast cancer subtypes, lacking expression of estrogen receptor, progesterone receptor, and HER2. Conventional chemotherapy and immune checkpoint inhibitors provide some benefit, but resistance and relapse are frequent. The search for novel targets has therefore become central to developing more effective and durable therapies. Recent advances in proteomics, structural biology, and targeted protein degradation are rapidly expanding the repertoire of actionable molecules in TNBC. This review summarizes current and emerging therapeutic strategies for TNBC, with a focus on targeted approaches designed to address tumor heterogeneity and resistance mechanisms. To this end, recent advances in targeted therapies are examined, including immune checkpoint inhibitors, PARP inhibitors, Trop-2–directed antibody–drug conjugates, anti-angiogenic agents, PI3K/Akt/mTOR pathway inhibitors, androgen receptor antagonists, and CDK4/6 inhibitors, highlighting results from completed and ongoing clinical trials. In addition, we explore novel targets identified through integrative omics approaches, as well as the role of the tumor metabolism and microenvironment in modulating therapeutic efficacy. Finally, we outline innovative radiotherapy strategies based on targeted radiation delivery and biological integration with systemic therapies. Collectively, this review provides an updated and novel overview of the evolving TNBC therapeutic landscape and highlights promising directions for the development of next-generation, biomarker-driven treatment strategies aimed at improving patient outcomes, maintaining a broad perspective on a very large class of targets.

13 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
APAndrea Previtali
Andrea Previtali
IGIsabella Guardamagna
Isabella Guardamagna
SCSilvia Calandra
Silvia Calandra
MSMaryam Shakarami
Maryam Shakarami
LLLEONARDO LONATI
LEONARDO LONATI
Claudia ScottiClaudia Scotti
Claudia Scotti
Triple-negative breast cancer (TNBC) remains one of the most aggressive and therapeutically challenging breast cancer subtypes, lacking expression of estrogen receptor, progesterone receptor, and HER2. Conventional chemotherapy and immune check-point inhibitors provide some benefit, but resistance and relapse are frequent. The search for novel targets has therefore become central to developing more effective and durable therapies. Recent advances in proteomics, structural biology, and targeted protein degradation are rapidly expanding the repertoire of actionable molecules in TNBC. This review summarizes current and emerging therapeutic strategies for TNBC, with a focus on targeted approaches designed to address tumor heterogeneity and resistance mechanisms. To the aim, recent advances in targeted therapies are examined, including immune checkpoint inhibitors, PARP inhibitors, Trop-2–directed antibody–drug conjugates, anti-angiogenic agents, PI3K/Akt/mTOR pathway inhibitors, androgen receptor antagonists, and CDK4/6 inhibitors, highlighting results from completed and ongoing clinical trials. In addition, we explore novel targets identified through integrative omics approaches, as well as the role of the tumor microenvironment in modulating therapeutic efficacy. Finally, we outline innovative radiotherapy strategies based on targeted radiation delivery and biological integration with systemic therapies. Collectively, this review provides an updated overview of the evolving TNBC therapeutic landscape and high-lights promising directions for the development of next-generation, biomarker-driven treatment strategies aimed at improving patient outcomes.

28 March 2025 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
MUMaria Giulia Ubeira-Gabellini
Maria Giulia Ubeira-Gabellini
GPGabriele Palazzo
Gabriele Palazzo
MMMartina Mori
Martina Mori
ATAlessia Tudda
Alessia Tudda
LRLuciano Rivetti
Luciano Rivetti
Claudio FiorinoClaudio Fiorino
Claudio Fiorino
In order to optimize the radiotherapy treatment and minimize toxicities, organs-at-risk (OARs) and clinical target volume (CTV) must be segmented. Deep Learning (DL) techniques show significant potential for performing this task effectively. The availability of a large single-institute data sample, combined with additional numerous multi-centric data, makes it possible to develop and validate a reliable CTV segmentation model. Planning CT data of 1822 patients were available (861 from a single center for training and 961 from 8 centers for validation). A preprocessing step, aimed at standardizing all the images, followed by a 3D-Unet capable of segmenting both right and left CTVs was implemented. The metrics used to evaluate the performance were the Dice similarity coefficient (DSC), the Hausdorff distance (HD), and its 95th percentile variant (HD_95) and the Average Surface Distance (ASD). The segmentation model achieved high performance on the validation set (DSC: 0.90; HD: 20.5 mm; HD_95: 10.0 mm; ASD: 2.1 mm; epoch 298). Furthermore, the model predicted smoother contours than the clinical ones along the cranial–caudal axis in both directions. When applied to internal and external data the same metrics demonstrated an overall agreement and model transferability for all but one (Inst 9) center. . A 3D-Unet for CTV segmentation trained on a large single institute cohort consisting of planning CTs and manual segmentations was built and externally validated, reaching high performance.

28 November 2025 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Open access
RCRebecca Castel
Rebecca Castel
AMAlice Mentana
Alice Mentana
VTVirginie Tassistro
Virginie Tassistro
CRCecilia Riani
Cecilia Riani
MPMickaël Payet
Mickaël Payet
TOThierry Orsière
Thierry Orsière
Tritium is a byproduct of nuclear fission activities and permeates in building materials. Decommissioning nuclear power plants could release tritiated steel and cement particles in the environment that could be accidentally inhaled by workers in case of loss of containment. Although tritium is a low energy beta emitter, tritiated particles could remain for years in the lungs after inhalation and subject them to long-term beta radiation. The aim of this study was to advance knowledge in the field of the radiotoxicity of these tritiated particles on human alveolar macrophages, capable of phagocytizing these particles. Although no cytotoxicity was observed, exposure to steel particles induced a significant increase in the production of reactive oxygen species (ROS), whereas exposure to cement particles induced a slight increase of ROS. Despite inducing high oxidative stress, control hydrogenated steel particles did not induce any DNA damage. Control hydrogenated cement particles also induced little DNA damage. DNA damage was higher after particle tritiation. The tritiation led to larger fractions of cells with similar levels of DNA damage, particularly at the lowest concentration. Significant chromosomal damage occurred after exposure to hydrogenated and tritiated particles, but only tritiated particles induced a concentration-dependent response. Overall, our results suggest that hydrogenated particles are moderately genotoxic and the tritiation of the same particles enhances their genotoxic potential, especially increasing their clastogenic potential. The data highlight a specific toxicity of tritiated particles on alveolar macrophages and improves the current knowledge of tritiated particles.

10 September 2026 in Physica Medica
Verified
Journal Article
Closed access
FMF.S. Maddaloni
F.S. Maddaloni
SBS. Broggi
S. Broggi
AFAndrei Fodor
Andrei Fodor
GPG. Palazzo
G. Palazzo
MUMaria Giulia Ubeira-Gabellini
Maria Giulia Ubeira-Gabellini
Claudio FiorinoClaudio Fiorino
Claudio Fiorino